103 related articles for article (PubMed ID: 20005957)
1. Modest proteasomal inhibition by aberrant ubiquitin exacerbates aggregate formation in a Huntington disease mouse model.
de Pril R; Hobo B; van Tijn P; Roos RA; van Leeuwen FW; Fischer DF
Mol Cell Neurosci; 2010 Mar; 43(3):281-6. PubMed ID: 20005957
[TBL] [Abstract][Full Text] [Related]
2. Ubiquitin-proteasome system alterations in a striatal cell model of Huntington's disease.
Hunter JM; Lesort M; Johnson GV
J Neurosci Res; 2007 Jun; 85(8):1774-88. PubMed ID: 17455294
[TBL] [Abstract][Full Text] [Related]
3. Oxidative stress promotes mutant huntingtin aggregation and mutant huntingtin-dependent cell death by mimicking proteasomal malfunction.
Goswami A; Dikshit P; Mishra A; Mulherkar S; Nukina N; Jana NR
Biochem Biophys Res Commun; 2006 Mar; 342(1):184-90. PubMed ID: 16472774
[TBL] [Abstract][Full Text] [Related]
4. Proteasomal-dependent aggregate reversal and absence of cell death in a conditional mouse model of Huntington's disease.
Martín-Aparicio E; Yamamoto A; Hernández F; Hen R; Avila J; Lucas JJ
J Neurosci; 2001 Nov; 21(22):8772-81. PubMed ID: 11698589
[TBL] [Abstract][Full Text] [Related]
5. Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release.
Jana NR; Zemskov EA; Wang Gh ; Nukina N
Hum Mol Genet; 2001 May; 10(10):1049-59. PubMed ID: 11331615
[TBL] [Abstract][Full Text] [Related]
6. Low levels of mutant ubiquitin are degraded by the proteasome in vivo.
van Tijn P; Verhage MC; Hobo B; van Leeuwen FW; Fischer DF
J Neurosci Res; 2010 Aug; 88(11):2325-37. PubMed ID: 20336771
[TBL] [Abstract][Full Text] [Related]
7. Clearance of mutant huntingtin.
Li XJ; Li H; Li S
Autophagy; 2010 Jul; 6(5):663-4. PubMed ID: 20519964
[TBL] [Abstract][Full Text] [Related]
8. Modulating huntingtin half-life alters polyglutamine-dependent aggregate formation and cell toxicity.
Kaytor MD; Wilkinson KD; Warren ST
J Neurochem; 2004 May; 89(4):962-73. PubMed ID: 15140195
[TBL] [Abstract][Full Text] [Related]
9. Inhibiting the ubiquitin-proteasome system leads to preferential accumulation of toxic N-terminal mutant huntingtin fragments.
Li X; Wang CE; Huang S; Xu X; Li XJ; Li H; Li S
Hum Mol Genet; 2010 Jun; 19(12):2445-55. PubMed ID: 20354076
[TBL] [Abstract][Full Text] [Related]
10. Dose-dependent inhibition of proteasome activity by a mutant ubiquitin associated with neurodegenerative disease.
van Tijn P; de Vrij FM; Schuurman KG; Dantuma NP; Fischer DF; van Leeuwen FW; Hol EM
J Cell Sci; 2007 May; 120(Pt 9):1615-23. PubMed ID: 17405812
[TBL] [Abstract][Full Text] [Related]
11. Progressive phenotype and nuclear accumulation of an amino-terminal cleavage fragment in a transgenic mouse model with inducible expression of full-length mutant huntingtin.
Tanaka Y; Igarashi S; Nakamura M; Gafni J; Torcassi C; Schilling G; Crippen D; Wood JD; Sawa A; Jenkins NA; Copeland NG; Borchelt DR; Ross CA; Ellerby LM
Neurobiol Dis; 2006 Feb; 21(2):381-91. PubMed ID: 16150600
[TBL] [Abstract][Full Text] [Related]
12. Selective degeneration in YAC mouse models of Huntington disease.
Van Raamsdonk JM; Warby SC; Hayden MR
Brain Res Bull; 2007 Apr; 72(2-3):124-31. PubMed ID: 17352936
[TBL] [Abstract][Full Text] [Related]
13. Dynamic recruitment of active proteasomes into polyglutamine initiated inclusion bodies.
Schipper-Krom S; Juenemann K; Jansen AH; Wiemhoefer A; van den Nieuwendijk R; Smith DL; Hink MA; Bates GP; Overkleeft H; Ovaa H; Reits E
FEBS Lett; 2014 Jan; 588(1):151-9. PubMed ID: 24291262
[TBL] [Abstract][Full Text] [Related]
14. Single neuron ubiquitin-proteasome dynamics accompanying inclusion body formation in huntington disease.
Mitra S; Tsvetkov AS; Finkbeiner S
J Biol Chem; 2009 Feb; 284(7):4398-403. PubMed ID: 19074152
[TBL] [Abstract][Full Text] [Related]
15. Dopamine enhances motor and neuropathological consequences of polyglutamine expanded huntingtin.
Cyr M; Sotnikova TD; Gainetdinov RR; Caron MG
FASEB J; 2006 Dec; 20(14):2541-3. PubMed ID: 17065224
[TBL] [Abstract][Full Text] [Related]
16. Decreased expression of hypothalamic neuropeptides in Huntington disease transgenic mice with expanded polyglutamine-EGFP fluorescent aggregates.
Kotliarova S; Jana NR; Sakamoto N; Kurosawa M; Miyazaki H; Nekooki M; Doi H; Machida Y; Wong HK; Suzuki T; Uchikawa C; Kotliarov Y; Uchida K; Nagao Y; Nagaoka U; Tamaoka A; Oyanagi K; Oyama F; Nukina N
J Neurochem; 2005 May; 93(3):641-53. PubMed ID: 15836623
[TBL] [Abstract][Full Text] [Related]
17. Acute polyglutamine expression in inducible mouse model unravels ubiquitin/proteasome system impairment and permanent recovery attributable to aggregate formation.
Ortega Z; Díaz-Hernández M; Maynard CJ; Hernández F; Dantuma NP; Lucas JJ
J Neurosci; 2010 Mar; 30(10):3675-88. PubMed ID: 20220001
[TBL] [Abstract][Full Text] [Related]
18. Selective degeneration and nuclear localization of mutant huntingtin in the YAC128 mouse model of Huntington disease.
Van Raamsdonk JM; Murphy Z; Slow EJ; Leavitt BR; Hayden MR
Hum Mol Genet; 2005 Dec; 14(24):3823-35. PubMed ID: 16278236
[TBL] [Abstract][Full Text] [Related]
19. Mutant ubiquitin decreases amyloid β plaque formation in a transgenic mouse model of Alzheimer's disease.
van Tijn P; Dennissen FJ; Gentier RJ; Hobo B; Hermes D; Steinbusch HW; Van Leeuwen FW; Fischer DF
Neurochem Int; 2012 Oct; 61(5):739-48. PubMed ID: 22797007
[TBL] [Abstract][Full Text] [Related]
20. Huntington disease: new insights on the role of huntingtin cleavage.
Wellington CL; Leavitt BR; Hayden MR
J Neural Transm Suppl; 2000; (58):1-17. PubMed ID: 11128600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
